EMEA-002275-PIP01-17 - paediatric investigation plan

moxonidine

Key facts

• Active Substance:
  moxonidine
• Therapeutic area:
  Cardiovascular diseases
• Decision number:
  P/0228/2018
• PIP number:
  EMEA-002275-PIP01-17
• Pharmaceutical form(s):
  Film-coated tablet
• Condition(s) / indication(s):
  Treatment of hypertension
• Route(s) of administration:
  Oral use
• Decision type:
  RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)
• Decision date:
  29/07/2018

Decision

P/0228/2018: EMA decision of 29 July 2018 on the refusal of a product specific waiver for moxonidine (EMEA-002275-PIP01-17)

AdoptedReference Number: EMA/480848/2018